BRAF V600E for Treatment of Metastatic Melanoma

The FDA has approved Zelboraf (vemurafenib) for the treatment of BRAF V600E mutation-positive, inoperable or metastatic melanoma (skin cancer). In trials, the drug proved so effective the FDA fast-tracked the approval.

“The FDA approval of Zelboraf marks a major step forward in personalizing the treatment of metastatic melanoma, a devastating disease that until this year had limited approved treatment options,” said Hal Barron, M.D., chief medical officer and head, Global Product Development. “We will continue to study this medicine with a goal of further improving outcomes for people with melanoma and other cancers that are driven by BRAF mutations.”

PGXL provides BRAF genotyping on a 3 – 5 day turnaround.

by Content_Management
This entry was posted in Research. Bookmark the permalink.

One Response to BRAF V600E for Treatment of Metastatic Melanoma

  1. BRAF v600e says:

    Thanks for the nice blog. It was very useful for me. Keep sharing such ideas in the future as well. This was actually what I was looking for and I am glad to come here! Thanks for sharing such a valuable information with us
    BRAF v600e